Arvinas Showcases Promising Preclinical Data at AACR

An update from Arvinas Holding Company ( (ARVN) ) is now available.

On April 28, 2025, Arvinas presented preclinical data at the AACR annual meeting in Chicago, showcasing the investigational PROTAC BCL6 degrader, ARV-393. The studies demonstrated synergistic antitumor activity and complete tumor regressions when combined with standard chemotherapy, biologics, and investigational small molecule inhibitors in models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma. These findings highlight the potential for ARV-393 in combination therapies for lymphoma, supporting further evaluation in clinical settings.

Spark’s Take on ARVN Stock

According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.

Arvinas Holding Company shows potential with significant pipeline advancements and a strong cash position. However, the company struggles with profitability and cash flow management, reflected in its negative P/E ratio and challenging technical indicators. Positive corporate events and earnings call insights provide some optimism for future growth, yet the stock remains a speculative investment due to ongoing financial and operational challenges.

To see Spark’s full report on ARVN stock, click here.

More about Arvinas Holding Company

Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROteolysis TArgeting Chimera (PROTAC) platform. The company is working on investigational drugs for various conditions, including breast cancer, non-Hodgkin lymphoma, and neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut.

YTD Price Performance: -52.09%

Average Trading Volume: 2,354,025

Technical Sentiment Signal: Buy

Current Market Cap: $622.4M

See more data about ARVN stock on TipRanks’ Stock Analysis page.